Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $24.97 in the prior trading day, Janux Therapeutics Inc (NASDAQ: JANX) closed at $25.11, up 0.56%. In other words, the price has increased by $0.56 from its previous closing price. On the day, 0.53 million shares were traded. JANX stock price reached its highest trading level at $25.14 during the session, while it also had its lowest trading level at $24.53.
Ratios:
Our goal is to gain a better understanding of JANX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 47.03 and its Current Ratio is at 47.03. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on July 11, 2025, initiated with a Outperform rating and assigned the stock a target price of $65.
On December 03, 2024, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $63 to $70.
BTIG Research reiterated its Buy rating for the stock on December 03, 2024, while the target price for the stock was revised from $82 to $100.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 01 ’25 when Meyer Andrew Hollman sold 3,333 shares for $32.03 per share. The transaction valued at 106,745 led to the insider holds 82,139 shares of the business.
ANDREW MEYER bought 3,333 shares of JANX for $110,656 on May 01 ’25. On Apr 21 ’25, another insider, Meyer Andrew Hollman, who serves as the Chief Business Officer of the company, sold 3,334 shares for $30.00 each. As a result, the insider received 100,020 and left with 82,139 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 1508957824 and an Enterprise Value of 535137632. For the stock, the TTM Price-to-Sale (P/S) ratio is 3429.45 while its Price-to-Book (P/B) ratio in mrq is 1.50. Its current Enterprise Value per Revenue stands at 1218.992 whereas that against EBITDA is -3.748.
Stock Price History:
The Beta on a monthly basis for JANX is 2.84, which has changed by -0.42169505 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $21.97. The 50-Day Moving Average of the stock is 1.74%, while the 200-Day Moving Average is calculated to be -30.07%.
Shares Statistics:
The stock has traded on average 865.90K shares per day over the past 3-months and 981960 shares per day over the last 10 days, according to various share statistics. A total of 59.30M shares are outstanding, with a floating share count of 54.41M. Insiders hold about 9.45% of the company’s shares, while institutions hold 106.15% stake in the company. Shares short for JANX as of 1753920000 were 8733357 with a Short Ratio of 10.09, compared to 1751241600 on 10261166. Therefore, it implies a Short% of Shares Outstanding of 8733357 and a Short% of Float of 21.290001.
Earnings Estimates
The current assessment of Janux Therapeutics Inc (JANX) involves the perspectives of 7.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.75, with high estimates of -$0.38 and low estimates of -$1.22.
Analysts are recommending an EPS of between -$1.42 and -$2.74 for the fiscal current year, implying an average EPS of -$2.2. EPS for the following year is -$3.18, with 8.0 analysts recommending between -$1.87 and -$5.5.
